Ferenc Darvas, Ph.D.
Chairman of the Board, Founder
Serial innovator and entrepreneur with technical background and decade long business experience. Founded several companies in life-sciences research and development, specialized to optimizing drug and agrochemical compounds by nanotechnology since 2006. Dr. Darvas pioneered in adapting microfluidics and flow technologies for producing nanoparticles in early 2000’s.
Dr. Darvas developed the first industrialized solution-phase combinatorial synthesis technology (CMT), realized by ComGenex, the first European combinatorial chemistry corporation in 1992. In the mid-90′s he focused on high-throughput ADME methodologies in combinatorial design, introduced combinatorial methodologies into chemical genomics, and recently, the use of micro- and mesoscale flow reaction technologies for combinatorial synthesis and lead optimization, initiated and co-developed H-Cube®, the first bench top hydrogenator at ThalesNano, Inc.
Dr. Darvas received his first degree in organic chemistry, another in computer science, his PhD in the use of artificial intelligence in drug design, and the third degree is in patent law. He taught at several universities in Budapest, Barcelona, Gainesville serving as associate professor at the Florida International University in Miami. He is author of over 200 publications, co-editor of 25 books, inventor of over 100 patents. Co-founder of the International QSAR Society, Society for Biomolecular Screening (SBS, today SLAS), and the Flow Chemistry Society, where he is the Chairman, founder and editorial board member of the Journal of Flow Chemistry.
Member of the Board
Mr. Deak was CFO of Henkel Hungary in 1993 before becoming CEO and Chairman of Board of directors between 2003-2009 and he was simultaneously CFO of Henkel Czech Republic and Henkel in Slovakia. He was also appointed as the Sales and Marketing Director being responsible for the adhesive business. Ferenc was then made Corporate Director of Henkel AG and Co.KGaA in Dusseldorf before becoming CFO of Henkel Russia to help drive business in that region. He received his executive MBA degree at University of Edinburgh and ENCP Paris. Ferenc joined Darholding in 2013 and was appointed as Member of Board of Directors of Thalesnano, Cominnex and Aromax to advise them on direction, investment and partnership opportunities, and increase their profitability. In 2015 he moved to Luxemburg where he was the CFO in the Hungarian Broadcasting Division of RTL Group. After his return to Hungary, he continued to work for Darholding and from 1st of September he was appointed as CEO of InnoStudio Inc.
Attila Wootsch, Ph.D.
Member of the Board
Attila is an experienced company leader and project manager of R&D projects, mainly in the field of chemistry, renewable energy and agriculture, furthermore he is an accredited Executive Coach. From the beginning of his carrier, he has 10 years of experience as researcher, he worked first for the Hungarian Academy of Sciences and completed several fellowships, including post-doctoral work at Université de Poitiers in France, visiting scientist at MIT, Boston (USA), Firtz-Haber Institute, Berlin (Germany). He is expert in heterogenous catalysis, reactor design and engineering, hydrogen production, as well as synthesis of nano-particles. Attila headed the chemistry group at ThalesNano Inc for 3 years, he managed research projects for large pharmaceutical companies (such as Sanofi-Aventis, Bayern, GSK), contributed to reactor development and led the catalyst production department.
Attila has 7 years of experience with research and development projects funded by the European Commission framework programs, FP7 and H2020, respectively. He worked as head of project management at Invention and Research Centre and was the regional director of Ateknea Solutions Hungary for 2 years. Attila’s references include 51 publications in peer reviewed journals, one international and two Hungarian patent applications. He personally managed 13 EU funded projects with more than 20 million euros budget in total.
Attila holds PhD in chemical engineering from the Technical University of Budapest and MSc in economics from Corvinus University.
Georg Petroianu, M.D., Ph.D., FCP
Member of the Board
Dr. Petroianu is Chairman of the Dept. of Cellular Biology & Pharmacology and Associate Dean for Academic Affairs in the Florida International University (FIU) Herbert Wertheim College of Medicine. He previously served as Chair of Pharmacology and Therapeutics at the United Arab Emirates University (UAEU) after earning his MD, PhD and Habilitation from the University of Heidelberg/Mannheim. Dr. Petroianu has received numerous teaching awards, including Best Lecturer in Heidelberg/Mannheim, the Excellence in Teaching Award at the UAEU, Professor of the Year and Top Scholar at FIU. He was recognized as a leading pharmacology educator when he was inducted into the prestigious Academy of Pharmacology Educators of ASPET. He serves on the Pharmacology Test Material Development Committee of the US Medical Licensing Examination. He has written several books and book chapters and authored more than 165 peer-reviewed research papers. His research is related to organophosphate exposure. For his contribution to Pharmacology, Dr. Petroianu was awarded the Issekutz Medal of the Hungarian Society of Pharmacology and Toxicology and received an Honorary Doctoral Degree from Semmelweis University.